2.46
-0.01(-0.40%)
Currency In USD
| Previous Close | 2.47 |
| Open | 2.56 |
| Day High | 2.67 |
| Day Low | 2.45 |
| 52-Week High | 4.08 |
| 52-Week Low | 0.77 |
| Volume | 1.38M |
| Average Volume | 1.46M |
| Market Cap | 340.18M |
| PE | -6.83 |
| EPS | -0.36 |
| Moving Average 50 Days | 2.74 |
| Moving Average 200 Days | 1.75 |
| Change | -0.01 |
If you invested $1000 in Compass Therapeutics, Inc. (CMPX) since IPO date, it would be worth $289.41 as of March 15, 2025 at a share price of $2.46. Whereas If you bought $1000 worth of Compass Therapeutics, Inc. (CMPX) shares 3 years ago, it would be worth $1,597.4 as of March 15, 2025 at a share price of $2.46.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Compass Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
GlobeNewswire Inc.
Jan 29, 2025 1:00 PM GMT
BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced t
Compass Therapeutics Provides Corporate Update and Announces Advancement of a New Drug Candidate
GlobeNewswire Inc.
Jan 08, 2025 1:00 PM GMT
Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on track for end of Q1 2025.CTX-10726 (a novel PD-1 x VEGF-A bispecific) is advancing as a new drug candidat
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer
GlobeNewswire Inc.
Dec 10, 2024 1:00 PM GMT
BOSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced t